ABIVAX Société Anonyme
Paris Stock Exchange ABVX.PA
ABIVAX Société Anonyme Price to Sales Ratio (P/S) on January 14, 2025: 81.87
-
ABIVAX Société Anonyme 52-week high Price to Sales Ratio (P/S) is 205.55 on April 23, 2024, which is 151.06% above the current Price to Sales Ratio (P/S).
-
ABIVAX Société Anonyme 52-week low Price to Sales Ratio (P/S) is 81.87 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
-
ABIVAX Société Anonyme average Price to Sales Ratio (P/S) for the last 52 weeks is 151.14.
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
| CEO | Mr. Marc M. P. de Garidel M.B.A. |
| IPO Date | June 26, 2015 |
| Location | France |
| Headquarters | 5, rue de la Baume |
| Employees | 62 |
| Sector | Health Care |
| Industries | |
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Past 5 years
USD 3.05
USD 1.88
StockViz Staff
January 15, 2025
Any question? Send us an email